Cassady Schiller Wealth Management’s Cogent Biosciences COGT Stock Holding History

Cassady Schiller Wealth Management’s Portfolio COGT Stock Details COGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	$242	Buy	+31	New	+$309	﹤0.01%	1062

Other funds holding COGT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Cassady Schiller Wealth Management's COGT Position: Q4 2024 in Review

Cassady Schiller Wealth Management opened a new position in Cogent Biosciences (COGT) in Q4 2024: 31 shares worth $242. The stake represents ﹤0.01% of the portfolio and ranks #1062 among its holdings.

176 funds tracked by Wall St. Rank hold COGT as of Q4 2024.

Cassady Schiller Wealth Management held 31 shares of Cogent Biosciences worth $242 as of Q4 2024.
Cogent Biosciences was a new Cassady Schiller Wealth Management position in Q4 2024.
Cogent Biosciences made up ﹤0.01% of Cassady Schiller Wealth Management's portfolio in Q4 2024, its #1062 holding.
176 funds tracked by Wall St. Rank held Cogent Biosciences as of Q4 2024.

Based on Cassady Schiller Wealth Management's 13F filing for Q4 2024, filed 10 Feb 2025.